Jun. 4 at 5:14 PM
$MLTX because the abstract is axSpA Phase 2 rather than IZAR Phase 3 PsA, I would expect it to be a narrative accelerant, not the main rerating event.
The rheumatology signal is strong, safety remains clean, and imaging supports the mechanism.
VELA-52 and IZAR-1 are still the real stock-moving catalysts. The bullish implication is that if axSpA looks this good, confidence rises that IZAR-1 will be strong, too.
The pipeline in a product, strong platform, narrative increases. It does not replace IZAR, but it makes the IZAR setup more credible and gives MoonLake something substantial to discuss at EULAR/Goldman before the bigger HS/PsA data hit. https://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=sonelokimab&view=2&item=2026LB0002
